Eli Lilly, J&J Rise on New Data While Software Stocks Slide
Pharma giants Eli Lilly and J&J gained on fresh data releases, while software stocks reversed last week's advances heading into the final trading hour.
Eli Lilly and Johnson & Johnson shares climbed Wednesday after both companies released new data that buoyed investor confidence, even as the broader technology sector retreated and software stocks surrendered gains logged just days earlier. The divergence underscored a rotation dynamic playing out in real time across equity markets during the final hour of the regular trading session.
The afternoon moves came as part of the CNBC Investing Club's daily Homestretch briefing, an actionable market update designed to help investors navigate the closing stretch of the trading day. The Club flagged the pharma rally and the software pullback as the dominant themes shaping portfolio positioning heading into the close.
Read more VIX Drops to 2026 Low, but Strategists Urge Caution →
The software sector's reversal is notable because last week's gains had lifted sentiment around growth-oriented technology names, and Wednesday's retreat suggests that enthusiasm may have outpaced near-term fundamentals. Meanwhile, the positive data catalysts driving Lilly and J&J higher reflect ongoing investor appetite for names with concrete, data-backed news flow in a market still searching for clear directional signals.
The contrasting performances highlight how quickly sector leadership can rotate, particularly in an environment where macro uncertainty keeps traders reactive to individual company developments rather than broad index trends. Pharma's outperformance on data days versus tech's vulnerability to profit-taking remains a recurring pattern worth watching.
Continue reading at US Top News and Analysis.
